Price History

Hover for the daily close. The dotted line marks the period open.

Compare IXHL with… →

IXHL Key Statistics

As of Sep 4, 2026

Trading

Open: $3.22
Previous Close: $3.25
Day's Range: 3.22–3.31
52-Week Range: 2.49–20.31
Volume: 45.80K
Beta: 2.83

Valuation

Market Cap: $38.82M
P/E Ratio: unprofitable
EPS (ttm): −16.71

Financials (FY)

Revenue (FY): $12.00K
Net Income (FY): −$18.46M
Profit margin: 0.00%
Shares Outstanding: 11.96M
1-Year Return: −81.35%

Dividend and dates

Avg Volume: 189.68K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

IXHL Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

−81.18%−58.57%−54.31%−83.11%−69.79%

2022*2023202420252026*

Year	Return
2026 (partial year)	−69.79%
2025	−83.11%
2024	−54.31%
2023	−58.57%
2022 (partial year)	−81.18%

As of September 4, 2026.

IXHL Revenue and Earnings by Fiscal Year

FY ends June

RevenueNet income

202220232024

Fiscal year	Revenue	Net income	Net margin
2024	$12.00K	−$18.46M	−153825.0%
2023	$0.00	−$48.81M	—
2022	$0.00	−$10.25M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2024	$12.00K	—	−$18.61M	−$18.46M	−153825.0%
2023	$0.00	$0.00	−$13.64M	−$48.81M	—
2022	$0.00	−$4.36K	−$10.16M	−$10.25M	—

Annual figures as reported, in the company's reporting currency. As of June 30, 2024.

IXHL Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 103 stocks

Metric	IXHL	Drug Manufacturers - Specialty & Generic median	vs median
Profit margin	0.00%	−3.14%	3.1 pts above

Medians across 103 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

Incannex Healthcare Receives Final A$5.1M R&D Tax Incentive Refund Following Approval Of Its Overseas Findings And Amendment Of Its FY25 Tax Return
Benzinga2026-08-11

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Incannex Healthcare Inc. (IXHL) at $38.82M. It is classified in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector. Headcount on file is 12.

IXHL last closed at $3.25 on September 4, 2026. That is $0.00 (−0.15%) against the previous close. The 52-week range on file runs from $2.49 to $20.31. The latest close sits 30.32% above that 52-week low.

Financial Health

Fiscal 2024 revenue came to $12.00K. The same year closed with a net loss of $18.46M. Profit margin runs at 0%. That is 3.1 percentage points above the Drug Manufacturers - Specialty & Generic median of −3.14%. Earnings per share on a trailing basis come to −16.71.

Across the 3 fiscal years on file, revenue moves from $0.00 in 2022 to $12.00K in 2024. Of those 3 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Beta against the wider market is reported at 2.83. Annualized volatility over the trailing 4 years is 392.95%. The trailing one-year price return is −81.35%. Measured over 3 years, that is −73.54% a year compounded.

Growth & Income

The record shows no dividend for IXHL.

2026 is still running; the price is −69.79% year to date. Across the complete calendar years on file, 2024 returned −54.31% and 2025 returned −83.11%. Of the 3 complete calendar years on file, 0 finished higher.

Peer Comparison

Incannex Healthcare Inc. (IXHL) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Incannex Healthcare Inc.	IXHL	$38.82M	—
Takeda Pharmaceutical Company Limited	TAK	$58.92B	—
Teva Pharmaceutical Industries Limited	TEVA	$42.37B	60.6
Haleon plc	HLN	$42.22B	20.0

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 19.3x. Incannex Healthcare Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$58.92B

TEVA

Teva Pharmaceutical Industries Limited

$42.37B

HLN

Haleon plc

$42.22B

ZTS

Zoetis Inc.

$31.33B

UTHR

United Therapeutics Corporation

$20.91B

VTRS

Viatris Inc.

$19.39B

View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Incannex Healthcare Inc.

Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder. It is also developing IHL-675A, an oral fixed dose combination drug containing synthetic cannabidiol and hydroxychloroquine sulphate to treat rheumatoid arthritis, as well as lung inflammation, acute respiratory disease, chronic obstructive pulmonary disease, asthma, bronchitis, inflammatory bowel disease, colitis, and Crohn's disease. Incannex Healthcare Inc. is headquartered in Sydney, Australia.

Visit website →

Incannex Healthcare Inc. (IXHL) Stock Analysis